This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will LabCorp (LH) Gain on Rising Earnings Estimates?
by Zacks Equity Research
LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.
LabCorp (LH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 42.98% and 13.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.
LabCorp (LH) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength across its business segments.
Are Investors Undervaluing LabCorp (LH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. ALGN: Which Stock Is the Better Value Option?
Why LabCorp (LH) Could Beat Earnings Estimates Again
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow
by Zacks Equity Research
Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.
Here's Why LabCorp (LH) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain LabCorp (LH) Stock For Now
by Zacks Equity Research
Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).
LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit
by Zacks Equity Research
The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.
Labcorp (LH): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Labcorp (LH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sonos, Tencent, Quest Diagnostics, Quidel and LabCorp highlighted as Zacks Bull and Bear of the Day
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
by Zacks Equity Research
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
by Zacks Equity Research
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.